Navigation Links
UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
Date:1/20/2012

CLEVELAND, Jan. 20, 2012 /PRNewswire/ -- Patients with gynecologic cancer have new hope in a novel technology now offered at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center.  A team of cancer specialists, led by Robert DeBernardo, MD, is among the first in the nation to launch a dedicated program using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat ovarian, endometrial and select other cancers.

Performed immediately following surgery, HIPEC delivers heated chemotherapy through a 'hot bath' into the abdominal cavity, where it can penetrate diseased tissue directly.  After the surgeon removes as much visible cancer as possible, a heated, a sterilized chemotherapy solution is circulated throughout the abdomen through a technologically sophisticated perfusion system to destroy the remaining cancer cells. 

"This is a new and potentially revolutionary way of treating women with gynecologic cancers, which tend to be quite responsive to chemotherapy," says Dr. DeBernardo, gynecologic oncologist at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine. "Our preliminary data and experience has been overwhelmingly positive and the therapy has been well-tolerated and effective. HIPEC promises to extend lives in a meaningful way."   

HIPEC has been used for years in patients with colon, pseudomyxomas and appendiceal cancers as well as mesothelioma, cancers that in general are not responsive to chemotherapy, but it is now viewed as a promising new treatment for gynecologic malignancy.  

UH Case Medical Center plans to launch several Phase One trials for patients this spring, including a first-of-its kind study involving the use of heated chemotherapy for ovarian cancer that has spread to the thoracic cavity, a procedure called Hyperthermic Intrathoracic Chemotherapy (HITEC). These hard-to-treat cancers typically recur and HITEC is performed after minimally invasive lung surgery.

A second study is for advanced ovarian cancer patients in remission who have finished initial therapy of surgery and chemotherapy and then undergo HIPEC to prevent recurrence. A third study will involve patients whose cancer recurs and HIPEC is performed following surgical resection of their disease. A fourth is for patients on a neoadjuvant regimen who have had initial chemotherapy and HIPEC is incorporated into their surgery.

There are several advantages to HIPEC compared to traditional chemotherapy, including improved survival rates for gynecologic cancer patients. Previous studies on the use of chemotherapy given directly into the abdomen, known as intraperitoneal (IP) chemotherapy, have shown an extension of women's lives with advanced ovarian cancer on average of 1.5 years longer than women receiving intravenous (IV) treatment.

HIPEC allows a much higher dose of chemotherapy to permeate the diseased tissue. Because conventional chemotherapy is usually administered intravenously, it circulates throughout the body and is diluted by the time it reaches the abdomen. 

"Despite the obvious benefits, only a minority of women currently receive IP therapy due to practical difficulties involved in administering chemo directly in the abdomen following surgery," says Dr. DeBernardo. "HIPEC is now viewed as the next logical step in treating gynecologic cancers such as recurrent and new ovarian and certain endometrial cancers."

Additionally, there has been strong research demonstrating that heating the solution (hyperthermia) also enhances the power of the chemotherapy, improving absorption by tumors and susceptibility of cancer cells. Furthermore, because chemotherapy is kept within the abdomen, HIPEC minimizes the rest of the body's exposure to the treatment, which helps reduce some side effects such as hair loss.

In addition to gynecologic cancer patients, the multidisciplinary HIPEC team, comprised of surgical oncologists, medical oncologists, intensivists, chemotherapy nurses and perfusionists at UH Case Medical Center, is offering the procedure to patients with gastrointestinal cancers and mesothelioma.

"We believe this procedure can improve the odds for our patients and are eager to launch this series of clinical trials to further validate HIPEC's use in our patients," says Dr. DeBernardo.  "In our battle against cancer, we keep developing novel methods to outsmart the disease and HIPEC is yet another important tool in our war chest."

A video about UH Case Medical Center's HIPEC program can be viewed at: http://www.youtube.com/watch?v=kDtc2PKP1wc or for more information call the UH Seidman Cancer Center at 800-641-2422.

About University Hospitals
University Hospitals serves the needs of patients through an integrated network of hospitals, outpatient centers and primary care physicians.  At the core of our health system is University Hospitals Case Medical Center.  The primary affiliate of Case Western Reserve University School of Medicine, University Hospitals Case Medical Center is home to some of the most prestigious clinical and research centers of excellence in the nation and the world, including cancer, pediatrics, women's health, orthopedics and spine, radiology and radiation oncology, neurosurgery and neuroscience, cardiology and cardiovascular surgery, organ transplantation and human genetics. Its main campus includes the internationally celebrated UH Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. For more information, go to www.uhhospitals.org


'/>"/>
SOURCE University Hospitals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. First Choice Rehabilitation Specialists Joins Select Medical
2. inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health
3. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
4. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
5. Live Press Briefing on Findings of Biomedical Industry CEO Survey
6. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
7. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
8. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
9. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
10. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
11. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group and the ... as other research and development initiatives for potential stem cell protocol management for 2016 ... Cells Group executives began meeting to establish a working agenda and foster initiatives to ...
(Date:4/26/2016)... ... April 27, 2016 , ... Cameron Cushman ... as an associate in the firm’s Intellectual Property practice group. , Clients turn ... patent applications. He has an electrical engineering and computer engineering background, and experience ...
(Date:4/26/2016)... ... April 26, 2016 , ... Heidelberg Instruments, ... latest technology innovation for its Volume Pattern Generator (VPG) line of lithography systems. ... advanced photomasks as well as a solution for mid volume direct write lithography ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a biopharmaceutical research ... financing. Healthy investor interest drove significant oversubscription of the original $1.5M target. ... biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, Darryl ...
Breaking Biology Technology:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):